Page 3 - Yates Network News Today

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Ian T. Clark to its Board of Directors. Mr. Clark most recently served as Chief Executive Offi...

Search jobs 12-Jul-2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) ASP3772 has also received FDA Breakthrough Therapy Designation CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Affinivax, Inc. ("Affinivax") an...

Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal modelComplete protection from COVID-19 disease by a single dose skin patch delivery using Vaxxas’ HD-MAP was demonstrated in a lethal challenge of the SARS-...

Press release content from Business Wire. The AP news staff was not involved in its creation. Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer April 20, 2021 GMT Affinivax Chief Business Officer Stuart Chaffee PhD (Photo: Business Wire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 20, 2021-- Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platfor...

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks KVD900 Generally Safe and Well-Tolerated - Conference Call to Discuss Trial Results Today at 8:30 a.m. ET - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small ...

Sensei Biotherapeutics Announces Pricing of Upsized Initial Public Offering February 03, 2021 20:44 ET | Source: Sensei Biotherapeutics Sensei Biotherapeutics Gaithersburg, Maryland, UNITED STATES BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the pricing of its upsize...

Press release content from Business Wire. The AP news staff was not involved in its creation. Catamaran Bio Announces Appointment of Dr. Alvin Shih as President and Chief Executive Officer February 4, 2021 GMT Catamaran CEO Alvin Shih (Photo: Business Wire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 4, 2021-- Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat diseases with significant unmet medical need, today announced the appointment of Alvin Shih, M...

News Category Global Banking & Finance Reviews Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells -Phase 1a trial achieved primary objective of safety and tolerability -PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases -PT101 maintained selectivity for regulatory T...